KINTOR PHARMA-B Stock Forum

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

$KINTOR PHARMA-B (09939.HK)$
With the opening up, it is inevitable the Covid  cases will jump into hundreds of thousand. This is where this covid treatment drug will greatly benefit along with some of the other approved Covid  treatments

The latest US effort to reduce reliance on China is striking hard at the Asian nation’s biotech stocks, as investors price in more indications of decoupling between the world’s two biggest economies.  
Following US President Joe Biden’s executive order to bolster domestic bio-manufacturing and cut reliance on foreign companies, bellwether Chinese stocks such as $WUXI BIO (02269.HK)$ Wuxi Biologics Cayman Inc. and $WUXI APPTEC (02359.HK)$ WuXi AppT...

$KINTOR PHARMA-B (09939.HK)$
Kintor soared on news of Covid-19 drug efficacy.

Hang Seng pharmaceuticals sector slumps more than 6%, Kintor Pharma falls 20%, Fosun Pharma down 16% as investors cheer Merck's antiviral pill.
  $Pharmaceuticals (LIST1067.HK)$ 
  $FOSUN INTL (00656.HK)$ 
  $KINTOR PHARMA-B (09939.HK)$

$ALPHAMAB-B (09966.HK)$ $KINTOR PHARMA-B (09939.HK)$ $INNOVENT BIO (01801.HK)$ Today Hong Kong pharmaceutical and biotech stocks fell 2.36%, industry groups in Hong Kong or top 5, kill the biological medicine market valuation, capital is still wary of innovative drug, exploit medicine, corning jerry that is called a fall, but has strong industry leading cinda biology, growth of 4.16% in the pharmaceutical sector in the first, Market money still likes and likes a few big champions.